Analyst Ratings for Day One Biopharmaceutical
Portfolio Pulse from Benzinga Insights
Day One Biopharmaceutical (NASDAQ:DAWN) has received 4 bullish ratings from analysts in the last quarter, with no bearish or indifferent ratings. The company's average 12-month price target is $35.25, a decrease of 9.62% from the previous average of $39.00.
November 07, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One Biopharmaceutical has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, Day One Biopharmaceutical has received 4 bullish ratings in the last quarter, which indicates a positive outlook from analysts. This could increase investor confidence and potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100